Oscar Health, INC 8-K filings

Oscar Health announced record financial results for the first half of 2026, driven by strong operational performance and disciplined pricing, leading to a raised full-year outlook.

Oscar Health, Inc. announced the results of its 2026 Annual Meeting of Stockholders, confirming the election of eight director nominees and the approval of executive compensation and auditor ratification.

Oscar Health will participate in a fireside chat at the Goldman Sachs Global Healthcare Conference on June 8, 2026, to provide a business update and reaffirm its full-year 2026 guidance.

Oscar Health, Inc. has amended the employment agreement for Mario Schlosser, transitioning him from President of Technology and CTO to Co-Founder & Advisor to the CEO, effective June 1, 2026.

Oscar Health announced robust first-quarter 2026 financial results, showcasing significant year-over-year improvements and reaffirming its full-year guidance.

Oscar Health reaffirms its full-year 2026 financial guidance and announces a change in Board leadership, with Siddhartha Sankaran appointed as the new Independent Chair.

Oscar Health, Inc. announced its participation in the 2026 Raymond James Institutional Investors Conference, where it will reaffirm its full-year 2026 guidance.

Oscar Health announced a new $475 million revolving credit facility and reported a significant net loss for 2025, while projecting a return to profitability and substantial revenue growth in 2026.

Oscar Health, Inc. has extended CEO Mark T. Bertolini's employment agreement through April 2029, increasing his base salary and target bonus, and granting significant equity awards.

Oscar Health reported a wider net loss in Q3 2025 despite revenue growth and increased membership, while reaffirming its full-year 2025 financial guidance and executing a convertible notes exchange.

Oscar Health, Inc. successfully issued $410 million in 2.25% Convertible Senior Subordinated Notes due 2030 to fund strategic AI initiatives and growth.

Oscar Health announced the pricing of an upsized $355 million private offering of 2.25% convertible senior subordinated notes due 2030, intended to fund growth initiatives and terminate its revolving credit facility.

Oscar Health, Inc. announced a proposed private offering of $350 million in convertible senior subordinated notes due 2030 to fund growth initiatives and general corporate purposes.

Oscar Health, Inc. announced its participation in the 2025 Wells Fargo Healthcare Conference, where it will reaffirm its full year 2025 guidance.

Oscar Health, Inc. announced a significant net loss and increased medical loss ratio for the second quarter of 2025, while reaffirming its full-year 2025 guidance and projecting a return to profitability in 2026.

Oscar Health announced preliminary Q2 2025 losses and revised its full-year 2025 financial guidance, citing higher-than-expected ACA Marketplace risk scores and elevated member utilization.

Oscar Health, Inc. announced that its stockholders re-elected all nine director nominees, ratified the appointment of PricewaterhouseCoopers LLP as independent auditor, and approved executive compensation on an advisory basis at its 2025 Annual Meeting.

Oscar Health reports significant year-over-year increases in revenue and net income for the first quarter of 2025, reaffirming its full-year 2025 outlook.

Oscar Health reaffirms its full-year 2025 financial guidance previously provided in its Q4 2024 earnings release during the Raymond James Institutional Investors Conference.

Oscar Health reports its first profitable year in company history, driven by membership growth and improved cost management, and introduces its 2025 financial outlook.

Oscar Health announced a 68% year-over-year increase in revenue for the third quarter of 2024, alongside improvements in key financial metrics.

Oscar Health will reaffirm its full-year 2024 guidance at three upcoming healthcare conferences in September.

Oscar Health reported strong second-quarter results, including a 46% year-over-year revenue increase and a significant improvement in profitability, leading to an increased full-year revenue and adjusted EBITDA outlook.

Oscar Health held its 2024 Annual Meeting of Stockholders on June 6, 2024, where all director nominees were elected and proposals regarding the appointment of auditors and executive compensation were approved.

Oscar Health reaffirmed its full-year 2024 guidance and provided an update on its Adjusted EBITDA performance through April 2024 at its Investor Day.

Oscar Health reported a profitable first quarter of 2024 with significant year-over-year improvements in revenue, medical loss ratio, and SG&A expense ratio.

Oscar Health reported strong 2023 financial results, exceeding expectations and setting a positive outlook for 2024, including projected total company adjusted EBITDA profitability.